Horacio Capote, MD
Psychiatry · Amherst, NYNPI 1053475939
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $720,665 of the $1,066,834 with a category attached, or 67.6%. 47 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 25.0% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,471 payments — averaging $431.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$267K
- Otsuka America Pharmaceutical, Inc.$253K
- Johnson & Johnson$241K
- Acadia Pharmaceuticals Inc$84K
- Teva Pharmaceuticals USA, Inc.$75K
- Sunovion Pharmaceuticals Inc.$70K
- plus $77K from 41 others
Across 265 payments — averaging $4500.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$501K
- Eisai Inc.$241K
- E.r. Squibb & Sons, L.L.C.$186K
- Acadia Pharmaceuticals Inc$157K
- Livanova USA, Inc.$67K
- Genentech, Inc.$18K
- plus $23K from 3 others
Across 7 payments — averaging $14,547 each. An ownership or investment interest held by the physician or an immediate family member.
- Neurology Practice Consortium GPO, LLC$102K
What the payments were for
- Consulting fees$121,68811%
- Speaking & faculty fees$720,66568%
- Grants$36,4453%
- Travel & lodging$139,16713%
- Food & beverage$48,5665%
- Education$3030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$263,072
- SPRAVATO$235,977
- REXULTI$232,708
- NUPLAZID$83,043
- LATUDA$67,565
- AUSTEDO$45,758
- Auvelity$28,455
- Austedo XR$26,916
- VRAYLAR$20,832
- ABILIFY MAINTENA$17,662
- Lucemyra/Lofexidine$1,644
- SUNOSI$1,625
- QUVIVIQ$1,418
- QELBREE$472
- UBRELVY$160
- COBENFY$125
- NURTEC ODT$111
- INGREZZA$107
How this compares
$1,066,834 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 72 | $120,371 |
| Invega SustennaPaliperidone Palmitate | 30 | $102,648 |
| NuplazidPimavanserin Tartrate | 18 | $90,775 |
| RexultiBrexpiprazole | 48 | $68,546 |
| VraylarCariprazine Hcl | 37 | $65,314 |
| Abilify MaintenaAripiprazole | 21 | $58,285 |
| NuedextaDextromethorphan Hbr/Quinidine | 30 | $56,352 |
| TrintellixVortioxetine Hydrobromide | 62 | $48,861 |
| AristadaAripiprazole Lauroxil | 12 | $38,288 |
| FanaptIloperidone | 12 | $28,841 |
| Aripiprazole | 229 | $9,287 |
| Lurasidone Hcl | 36 | $3,555 |
| Paliperidone ErPaliperidone | 30 | $3,457 |
| Duloxetine Hcl | 180 | $3,399 |
| Vilazodone Hcl | 23 | $2,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $252,964 | $126,83169 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $266,883 | $120,37172 claims |
| Johnson & JohnsonInvega Sustenna | $240,678 | $102,64830 claims |
| Acadia Pharmaceuticals IncNuplazid | $84,348 | $90,77518 claims |
| AbbVieVraylar | $22,921 | $65,31437 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $638 | $56,35230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $580 | $48,86162 claims |
| Alkermes, Inc.Aristada | $1,699 | $38,28812 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,237 | $28,84112 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $80061 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Amherst
- Adam AshtonAmherst$1.6M
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Yadagiri ChepuruYonkers$963K
- Ulla Kristina LaaksoNew York$890K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.